Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 3/20 | 0.38 |
| ▸ | KCNA5 | P22460 | 9/20 | 0.37 |
| ▸ | GLS | O94925 | 1/20 | 0.36 |
| ▸ | POLR1A | O95602 | 1/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4192654 | 1.00 | ACKR3 (0.38) | ACKR3KCNA5GLSPOLR1APDE3B | |
| SCHEMBL4185887 | 0.83 | ACKR3 (0.42) | ACKR3KCNA5GLSPOLR1APDE3B | |
| SCHEMBL4185884 | 0.83 | ACKR3 (0.42) | ACKR3KCNA5GLSPOLR1APDE3B | |
| SCHEMBL4192631 | 0.82 | ABCB1 (0.39) | ACKR3KCNA5GLSABCB1 | |
| SCHEMBL4187959 | 0.82 | ABCB1 (0.39) | ACKR3KCNA5GLSABCB1 | |
| SCHEMBL4188579 | 0.77 | KCNA5 (0.35) | KCNA5ABCB1 | |
| SCHEMBL12678195 | 0.76 | KCNA5 (0.39) | ACKR3KCNA5GLS | |
| SCHEMBL4185562 | 0.74 | KCNA5 (0.49) | KCNA5 | |
| SCHEMBL4185560 | 0.74 | KCNA5 (0.49) | KCNA5 | |
| SCHEMBL4194445 | 0.74 | KCNA5 (0.49) | KCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273905-B2 | Aminoalkyl-amidomethyl-substituted 2-(4-sulphonylamino)-3-hydroxy-3,4-dihydro-2H-chroman-6-yl derivatives | ABBOTT PRODUCTS GMBH (DE) | 2012-09-25 | — | — | US | disclosed |
| US-20090203686-A1 | Aminoalkyl-Amidomethyl-Substituted 2-(4-Sulphonylamino)- 3-Hydroxy-3,4-Dihydro-2H-Chroman-6-yl Derivatives | SOLVAY PHARMACEUTICALS GMBH (DE) | 2009-08-13 | — | — | US | disclosed |
| CN-101160301-A | Aminoalkyl-amidomethyl-substituted 2- (4-sulfonylamino) -3-hydroxy-3, 4-dihydro-2H-chromen-6-yl derivatives and their use as potassium channel blockers | SOLVAY PHARM GMBH (DE) | 2008-04-09 | — | — | CN | disclosed |
| US-20060252821-A1 | Aminoalkyl-amidomethyl-substituted 2-(4-sulphonylamino)-3-hydroxy-3,4-dihydro-2H-chroman-6-yl derivatives | SOLVAY PHARMACEUTICALS GMBH | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252821-A1 | Aminoalkyl-amidomethyl-substituted 2-(4-sulphonylamino)-3-hydroxy-3,4-dihydro-2H-chroman-6-yl derivatives | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PRMT9, ABCC9 | ACKR3 463/4885KCNA5 929/4885GLS 888/4885 |
| US-20090203686-A1 | Aminoalkyl-Amidomethyl-Substituted 2-(4-Sulphonylamino)- 3-Hydroxy-3,4-Dihydro-2H-Chroman-6-yl Derivatives | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PRMT9, ARG1 | ACKR3 611/4885KCNA5 1080/4885GLS 857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.